KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CRISPR Therapeutics AG (CRSP) FCF Margin (2016 - 2025)

CRISPR Therapeutics AG (CRSP) has disclosed FCF Margin for 10 consecutive years, with 10771.99% as the latest value for Q4 2025.

  • Quarterly FCF Margin fell 1063600.0% to 10771.99% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 9855.5% through Dec 2025, down 947246.0% year-over-year, with the annual reading at 9855.5% for FY2025, 947246.0% down from the prior year.
  • FCF Margin hit 10771.99% in Q4 2025 for CRISPR Therapeutics AG, down from 9528.46% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 21633.13% in Q1 2024 to a low of 2426616.67% in Q4 2022.
  • Historically, FCF Margin has averaged 143253.77% across 5 years, with a median of 10771.99% in 2025.
  • Biggest five-year swings in FCF Margin: plummeted -242644717bps in 2022 and later surged 242657290bps in 2023.
  • Year by year, FCF Margin stood at 169.5% in 2021, then crashed by -1431519bps to 2426616.67% in 2022, then surged by 100bps to 43.77% in 2023, then plummeted by -211bps to 136.0% in 2024, then plummeted by -7821bps to 10771.99% in 2025.
  • Business Quant data shows FCF Margin for CRSP at 10771.99% in Q4 2025, 9528.46% in Q3 2025, and 12779.93% in Q2 2025.